STOCK MARKET BSE NSE

Zydus Cadila seeks DCGI nod for human clinical trials of antibodies cocktail to treat COVID-19

Cadila Healthcare is the listed entity of the group. ZRC-3308 has been found to be safe and well tolerated in animal toxicology studies.

Published: 27th May 2021 11:12 AM  |   Last Updated: 27th May 2021 11:12 AM   |  A+A-

Zydus Cadila plant

Representational image

By PTI

NEW DELHI: Zydus Cadila on Thursday said it is seeking permission from Drugs Controller General of India (DCGI) to initiate human clinical trials for monoclonal antibodies cocktail for treatment of COVID-19.

"Zydus is currently seeking permission to initiate phase 1/3 human clinical trials from the DCGI...ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID 19," Cadila Healthcare said in a regulatory filing.

Cadila Healthcare is the listed entity of the group. ZRC-3308 has been found to be safe and well tolerated in animal toxicology studies. Zydus said it is the only Indian company to have developed a neutralizing monoclonal antibody based cocktail for the treatment of COVID-19.

Dr Sharvil Patel, Managing Director, Cadila Healthcare Ltd said, "At this juncture, there is a critical need to explore safer and more efficacious treatments to combat COVID. It is important to look at different stages of the disease progression and look at options that can reduce patient's suffering and discomfort. We believe that ZRC-3308 has the potential to address these concerns and provide a safe treatment."

Earlier this week, drug majors Roche India and Cipla announced the launch of Roche's Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

edexworks
flipboard facebook twitter whatsapp